Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 18, 2019Clinical Cancer ResearchOpen Access

Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

JMJun MaUniversity of PennsylvaniaXQXinan QiaoJilin UniversityTKTristan KnightUniversity of Hawaiʻi at Mānoa

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ma et al. (2019) studied this question.

synapsesocial.com/papers/6a8aa6ebec2e105e8ac15c56https://doi.org/10.1158/1078-0432.ccr-19-0832
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells2016 · 248 citations
  2. 2Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia2005 · 107 citations
  3. 3Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells2012 · 23 citations
  4. 4Inhibition of <scp>XPO</scp>1 enhances cell death induced by <scp>ABT</scp>‐199 in acute myeloid leukaemia via Mcl‐12018 · 63 citations
  5. 5Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT32010 · 506 citations